EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity

Sarah Falk, Jonas Petersen, Charlotte Svendsen, Cesar R Romero-Leguizamón, Søren Heide Jørgensen, Nathalie Krauth, Mette Q Ludwig, Kathrine Lundø, Urmas Roostalu, Grethe Skovbjerg, Duy Anh Gurskov Nielsen, Aske Lykke Ejdrup und 6 weitere

Cell Reports · 2023-05 · 42 (5) · 112466

DOI: 10.1016/j.celrep.2023.112466 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2023-05. Verfasst von Sarah Falk und 17 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Liraglutide. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Københavns Universitet, Lundbeck Foundation, Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 receptor (GLP-1R) agonists promote nicotine avoidance. Here, we show that the crosstalk between GLP-1 and nicotine extends beyond effects on nicotine self-administration and can be exploited pharmacologically to amplify the anti-obesity effects of both signals. Accordingly, combined treatment with nicotine and the GLP-1R agonist, liraglutide, inhibits food intake and increases energy expenditure to lower body weight in obese mice. Co-treatment with nicotine and liraglutide gives rise to neuronal activity in multiple brain regions, and we demonstrate that GLP-1R agonism increases excitability of hypothalamic proopiomelanocortin (POMC) neurons and dopaminergic neurons in the ventral tegmental area (VTA). Further, using a genetically encoded dopamine sensor, we reveal that liraglutide suppresses nicotine-induced dopamine release in the nucleus accumbens in freely behaving mice. These data support the pursuit of GLP-1R-based therapies for nicotine dependence and encourage further evaluation of combined treatment with GLP-1R agonists and nicotinic receptor agonists for weight loss.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide 1LiraglutideMiceAnimalsNicotineDopamineObesity

Stichwörter der Autor:innen

CP: MetabolismCP: NeuroscienceGLP-1body weightenergy balancefood intakenicotineobesitypharmacologyreward

Substanzen

Glucagon-Like Peptide 1LiraglutideNicotineDopamine

Autor:innen und Institutionen

  • Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Drug Design and Pharmacology, Faculty of Health and Medic…
  • Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Neuroscience, Faculty of Health and Medical Sciences, Uni…
  • Gubra, Hørsholm, Denmark.

Förderung

  • Københavns Universitet
  • Lundbeck Foundation
  • Novo Nordisk Fonden

Zitieren

APA

Falk, S., Petersen, J., Svendsen, C., Romero-Leguizamón, C. R., Jørgensen, S. H., Krauth, N., Ludwig, M. Q., Lundø, K., Roostalu, U., Skovbjerg, G., Nielsen, D. A. G., Ejdrup, A. L., Pers, T. H., Dmytriyeva, O., Hecksher-Sørensen, J., Gether, U., Kohlmeier, K. A., & Clemmensen, C. (2023). GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity. Cell Reports, 42(5), 112466. https://doi.org/10.1016/j.celrep.2023.112466

Vancouver

Falk S, Petersen J, Svendsen C, Romero-Leguizamón CR, Jørgensen SH, Krauth N, et al. GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity. Cell Reports. 2023;42(5):112466. doi:10.1016/j.celrep.2023.112466

BibTeX
@article{Falk2023,
  author = {Falk, Sarah and Petersen, Jonas and Svendsen, Charlotte and Romero-Leguizamón, Cesar R and Jørgensen, Søren Heide and Krauth, Nathalie and Ludwig, Mette Q and Lundø, Kathrine and Roostalu, Urmas and Skovbjerg, Grethe and Nielsen, Duy Anh Gurskov and Ejdrup, Aske Lykke and Pers, Tune H and Dmytriyeva, Oksana and Hecksher-Sørensen, Jacob and Gether, Ulrik and Kohlmeier, Kristi A and Clemmensen, Christoffer},
  title = {GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity},
  journal = {Cell Reports},
  year = {2023},
  volume = {42},
  number = {5},
  pages = {112466},
  doi = {10.1016/j.celrep.2023.112466}
}
Kostenlos starten →